Session Details

Session Details

01:30 PM - 03:15 PM - Ballroom 2

Nicole Paulk - PhD - Siren Biotechnology

Co-Chair

01:30 PM - 03:15 PM - Ballroom 2

Nicolas Wein - PhD - Center for Gene Therapy - Nationwide Children's Hospital

Co-Chair

01:30 PM - 01:45 PM - Ballroom 2

Daniella Munezero - PhD - Nationwide Children's Hospital

18: Breaking Ground in CMT1B Treatment: AAV9-Mediated Dual RNAi and Gene Replacement Therapy Targeting Schwann Cells Improves Myelination and Peripheral Nerve Function in Mice

01:45 PM - 02:00 PM - Ballroom 2

Brooke Babineau - PhD - Encoded Therapeutics

19: GABA Selective AAV-Mediated Gene Therapy Provides Durable Seizure Protection in Multiple Refractory Epilepsy Models

02:00 PM - 02:15 PM - Ballroom 2

Henry Lee - Senior Scientist - Boston Children's Hospital

20: Curable Hyperactive Behaviors and Serum Biomarkers upon Gene Replacement Therapy in Succinic Semialdehyde Dehydrogenase Deficiency in Mice

02:15 PM - 02:30 PM - Ballroom 2

Sehar Riaz - MPhil - University of Maryland, School of Medicine

21: From Darkness to Light: CIB2 Gene Delivery Rescues Age-Related Macular Degeneration-Like Phenotype in a Preclinical Model

02:30 PM - 02:45 PM - Ballroom 2

Tomoko Hasegawa - MD PhD - University of North Carolina at Chapel Hill

22: Prevention of High-Risk Allogeneic Corneal Transplant Rejection by AAV-Mediated Transfer of Novel Anti-Inflammatory Immunomodulator

02:45 PM - 03:00 PM - Ballroom 2

Nandaki Keshavan - MA MB BChir PhD - University College London

23: Neonatal AAV9 Gene Therapy Prevents Hepatic Mitochondrial Dysfunction in a Mouse Model of DGUOK Deficiency

03:00 PM - 03:15 PM - Ballroom 2

Wassamon Boonying - PhD - University of Massachusetts Chan Medical School

24: AAV9 Delivered Artificial microRNAs Effectively Improves GFAP Pathology and Motor Impairment in an Alexander Disease Rat Model